Novel ‘3D’ Stent Improves Clinical Status in Femoropopliteal Disease Patients

PARIS, France—A "3D" helical stent that mimics the natural vascular curvature helps improve clinical symptoms and walking distance at 12 months in patients with femoropopliteal disease, according to results presented Tuesday, May 21 at EuroPCR 2013.

For the Mimics study, researchers led by Stephan H. Duda, MD, of Jewish Hospital Berlin (Berlin, Germany), randomized 76 patients with Rutherford 1to 4 occlusions of the SFA/proximal popliteal artery to receive the BioMimics 3D stent (Veryan, Horsham, United Kingdom) or a control stent (24/26 LifeStent, CR Bard, Murray Hill, NJ).

The BioMimics 3D stent features a 3-dimensional design that mimics the natural helical geometry of the human vascular system. The intention is to improve blood flow characteristics in the stented segment that may confer a vasoprotective effect and enhance biomechanical performance. The stent is also designed to promote swirling flow to elevate wall shear stress.
At 12 months, event-free survival (freedom from MAE, amputation, or clinically driven TLR) was 89.3% with BioMimics vs. 92.3% with control stents (P = 0.191), while Kaplan Meier primary patency was 80.4% with BioMimics vs. 72.0% with control stents (P = 0.105).